Logo image of MGRX

MANGOCEUTICALS INC (MGRX) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:MGRX - US56270V2051 - Common Stock

1.11 USD
+0.04 (+3.74%)
Last: 11/28/2025, 1:30:01 PM
Fundamental Rating

1

We assign a fundamental rating of 1 out of 10 to MGRX. MGRX was compared to 39 industry peers in the Consumer Staples Distribution & Retail industry. MGRX has a bad profitability rating. Also its financial health evaluation is rather negative. MGRX does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year MGRX has reported negative net income.
MGRX had a negative operating cash flow in the past year.
MGRX Yearly Net Income VS EBIT VS OCF VS FCFMGRX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2021 2022 2023 2024 -2M -4M -6M -8M

1.2 Ratios

With a Return On Assets value of -68.14%, MGRX is not doing good in the industry: 92.31% of the companies in the same industry are doing better.
MGRX has a worse Return On Equity (-73.81%) than 84.62% of its industry peers.
Industry RankSector Rank
ROA -68.14%
ROE -73.81%
ROIC N/A
ROA(3y)-377.5%
ROA(5y)N/A
ROE(3y)-525.62%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
MGRX Yearly ROA, ROE, ROICMGRX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2021 2022 2023 2024 0 -200 -400 -600 -800 -1K

1.3 Margins

The Gross Margin of MGRX (61.02%) is better than 97.44% of its industry peers.
The Profit Margin and Operating Margin are not available for MGRX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 61.02%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
MGRX Yearly Profit, Operating, Gross MarginsMGRX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2021 2022 2023 2024 0 -5K -10K -15K -20K

More info and screens

1

2. Health

2.1 Basic Checks

MGRX does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for MGRX has been increased compared to 1 year ago.
The debt/assets ratio for MGRX is higher compared to a year ago.
MGRX Yearly Shares OutstandingMGRX Yearly Shares OutstandingYearly Shares Outstanding 2021 2022 2023 2024 1M 2M 3M
MGRX Yearly Total Debt VS Total AssetsMGRX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2022 2023 2024 5M 10M 15M

2.2 Solvency

Based on the Altman-Z score of 1.13, we must say that MGRX is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of MGRX (1.13) is worse than 82.05% of its industry peers.
A Debt/Equity ratio of 0.03 indicates that MGRX is not too dependend on debt financing.
MGRX has a Debt to Equity ratio of 0.03. This is amongst the best in the industry. MGRX outperforms 87.18% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.03
Debt/FCF N/A
Altman-Z 1.13
ROIC/WACCN/A
WACC8.62%
MGRX Yearly LT Debt VS Equity VS FCFMGRX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 2023 2024 0 5M -5M 10M

2.3 Liquidity

MGRX has a Current Ratio of 0.07. This is a bad value and indicates that MGRX is not financially healthy enough and could expect problems in meeting its short term obligations.
Looking at the Current ratio, with a value of 0.07, MGRX is doing worse than 97.44% of the companies in the same industry.
MGRX has a Quick Ratio of 0.07. This is a bad value and indicates that MGRX is not financially healthy enough and could expect problems in meeting its short term obligations.
The Quick ratio of MGRX (0.07) is worse than 97.44% of its industry peers.
Industry RankSector Rank
Current Ratio 0.07
Quick Ratio 0.07
MGRX Yearly Current Assets VS Current LiabilitesMGRX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2022 2023 2024 500K 1M

More info and screens

0

3. Growth

3.1 Past

MGRX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 33.35%, which is quite impressive.
The Revenue for MGRX has decreased by -40.47% in the past year. This is quite bad
EPS 1Y (TTM)33.35%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%60.52%
Revenue 1Y (TTM)-40.47%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%3%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
MGRX Yearly Revenue VS EstimatesMGRX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2022 2023 2024 200K 400K 600K

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

MGRX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
MGRX Price Earnings VS Forward Price EarningsMGRX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MGRX Per share dataMGRX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 -2 -3

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for MGRX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

MANGOCEUTICALS INC

NASDAQ:MGRX (11/28/2025, 1:30:01 PM)

1.11

+0.04 (+3.74%)

Chartmill FA Rating
GICS SectorConsumer Staples
GICS IndustryGroupConsumer Staples Distribution & Retail
GICS IndustryConsumer Staples Distribution & Retail
Earnings (Last)11-14 2025-11-14/amc
Earnings (Next)03-20 2026-03-20
Inst Owners2.77%
Inst Owner Change-1.56%
Ins Owners12.86%
Ins Owner Change16.82%
Market Cap15.44M
Revenue(TTM)516.10K
Net Income(TTM)-14.20M
AnalystsN/A
Price TargetN/A
Short Float %1.99%
Short Ratio0.08
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 29.92
P/FCF N/A
P/OCF N/A
P/B 0.8
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-3.33
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.42
FCFYN/A
OCF(TTM)-0.42
OCFYN/A
SpS0.04
BVpS1.38
TBVpS-0.1
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -68.14%
ROE -73.81%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 61.02%
FCFM N/A
ROA(3y)-377.5%
ROA(5y)N/A
ROE(3y)-525.62%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.02
Health
Industry RankSector Rank
Debt/Equity 0.03
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.07
Quick Ratio 0.07
Altman-Z 1.13
F-Score3
WACC8.62%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)33.35%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%60.52%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-40.47%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%3%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-60.37%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y30.53%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y30.49%
OCF growth 3YN/A
OCF growth 5YN/A

MANGOCEUTICALS INC / MGRX FAQ

What is the fundamental rating for MGRX stock?

ChartMill assigns a fundamental rating of 1 / 10 to MGRX.


What is the valuation status for MGRX stock?

ChartMill assigns a valuation rating of 0 / 10 to MANGOCEUTICALS INC (MGRX). This can be considered as Overvalued.


What is the profitability of MGRX stock?

MANGOCEUTICALS INC (MGRX) has a profitability rating of 1 / 10.